By volume, Augmentin was way higher than Mounjaro with 5,784 units sold during October, compared to just 85 units sale of ...

A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly ...

Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER ...

KELOWNA, BC / ACCESS Newswire / March 18, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Over the past couple of years, Eli Lilly (NYSE: LLY) has emerged as the leader in the weight loss market. The company's ...

Eli Lilly (NYSE: LLY) stock has soared in the triple digits over the past three years thanks to one particular product line: its weight-loss drugs. Lilly is the maker of tirzepatide, sold under the ...

Lilly has submitted the results from SURPASS-PEDS to global regulatory agencies for an expanded indication. About tirzepatide Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

The deals are among the most politically significant announcements to date in the Trump administration's efforts to rein in ...

Eli Lilly (NYSE: LLY) is preparing to start Phase III trials of its experimental obesity therapy eloralintide by year-end, ...